About Mesoblast Limited
https://www.mesoblast.comMesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases.
CEO
Silviu Itescu
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-01-10 | Reverse | 1:2 |
| 2023-12-05 | Forward | 529:500 |
ETFs Holding This Stock
Summary
Showing Top 3 of 9
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
LEGAL & GENERAL GROUP PLC
Shares:651.42K
Value:$11.49M
BLACKROCK, INC.
Shares:540.42K
Value:$9.53M
MORGAN STANLEY
Shares:465.8K
Value:$8.22M
Summary
Showing Top 3 of 83
About Mesoblast Limited
https://www.mesoblast.comMesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $7.02M | $18.14M | $-27.1M | -386.04% | $-0.21 | $-19.64M |
| Q3-2025 | $7.02M ▲ | $18.14M ▼ | $-27.1M ▼ | -386.04% ▲ | $-0.21 | $-19.64M ▼ |
| Q2-2025 | $1.58M | $18.92M | $-23.97M | -1.52K% | $-0.21 | $-9.45M |
| Q1-2025 | $1.58M ▲ | $18.92M ▲ | $-23.97M ▲ | -1.52K% ▲ | $-0.21 ▲ | $-9.45M ▲ |
| Q4-2024 | $1.26M | $12.43M | $-27.71M | -2.2K% | $-0.25 | $-15.26M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $161.16M ▲ | $784.68M ▲ | $187.24M ▼ | $597.44M ▲ |
| Q2-2025 | $38.03M | $653.32M | $192.06M | $461.26M |
| Q1-2025 | $38.03M ▼ | $653.32M ▼ | $192.06M ▲ | $461.26M ▼ |
| Q4-2024 | $62.56M ▼ | $669.15M | $188.8M | $480.36M |
| Q3-2024 | $62.96M | $669.15M | $188.8M | $480.36M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-27.1M ▼ | $-16.62M ▼ | $-441K ▼ | $-4.83M ▼ | $-20.51M ▼ | $-14.94M ▼ |
| Q3-2025 | $0 ▲ | $-12.68M ▼ | $-66K ▼ | $156.43M ▲ | $144.03M ▲ | $-12.81M ▼ |
| Q2-2025 | $-23.97M ▼ | $-10.13M ▲ | $604K ▲ | $-2.33M ▼ | $-13.09M ▼ | $-10.38M ▲ |
| Q1-2025 | $0 | $-10.33M ▼ | $23K ▲ | $-1.94M ▲ | $-11.84M ▲ | $-10.57M ▼ |
| Q4-2024 | $0 | $0 | $-28K | $-3.02M | $-13.4M | $-86K |
CEO
Silviu Itescu
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-01-10 | Reverse | 1:2 |
| 2023-12-05 | Forward | 529:500 |
ETFs Holding This Stock
Summary
Showing Top 3 of 9
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
LEGAL & GENERAL GROUP PLC
Shares:651.42K
Value:$11.49M
BLACKROCK, INC.
Shares:540.42K
Value:$9.53M
MORGAN STANLEY
Shares:465.8K
Value:$8.22M
Summary
Showing Top 3 of 83